CAR T 세포 치료 시장 : 브랜드별, 표적 항원별, 적응증별 - 세계 예측(-2030년)

CAR T-cell Therapy Market Size, Share, Forecast, & Trends Analysis by Brand (Abecma [idecabtagene vicleucel], Breyanzi, Yescarta [axicabtagene ciloleucel]), Target Antigen (CD, BCMA, HER2) Indication (Lymphoma, ALL, AML)-Global Forecast to 2030.

The global CAR T-cell Therapy market is projected to reach $51.6 billion by 2030 at a CAGR of 43.3% from 2023 to 2030.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. This growth is due to increasing cancer prevalence, rise in awareness regarding CAR T-cell therapy, and increasing R&D activities and clinical trials. However, the complex manufacturing process and adverse effects of the therapy restrain the growth of this market.

Furthermore, the scope in emerging economies, innovation in cell therapies, and manufacturing processes are expected to generate growth opportunities for the players operating in this market. However, high cost of CAR T-cell therapy, and lack of skilled professionals are major challenges impacting market growth.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2023). The key players operating in the global CAR T-cell Therapy market are Novartis AG (Switzerland), bluebird bio, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Caribou Biosciences, Inc. (U.S.), Cartesian Therapeutics, Inc. (U.S.), Pfizer Inc. (U.S.), Cellectis S.A. (France), Celyad Oncology SA (Belgium), Gilead Sciences, Inc. (U.S.), Intellia Therapeutics, Inc. (U.S.), Merck & Co., Inc. (U.S.), Amgen Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), and OncoTherapy Science, Inc. (Japan).

Among all the drug types studied in this report, in 2023, the Yescarta (axicabtagene ciloleucel) segment is expected to account for the largest share of the CAR T-cell therapy market. Yescarta (axicabtagene ciloleucel) has demonstrated superior effectiveness compared to other treatments. It exhibits high efficacy in treating high-grade B-cell lymphoma (HGBL), diffuse large B-cell lymphoma (DLBCL), and primary mediastinal large B-cell lymphoma (PMBCL) that have not responded to previous therapies, establishing its dominance in the CAR T-cell therapy market.

Among all the target antigens studied in this report, in 2023, CD target antigen segment is projected to register the highest CAGR during the forecast period due to strong product pipeline, the increasing clinical trials focusing on the CD antigen therapies, and the ongoing research studies to develop the therapies focusing on the CD target antigen.

Among all the indications studied in this report, in 2023, the lymphoma segment is expected to account for the largest share of the CAR T-Cell therapy market. Lymphoma is a group of blood cancers that develop from abnormal white blood cells or lymphocytes. Due to the increased cases of lymphoma, there was a rise in the adoption of CAR T-cell therapy for treating lymphoma, contributing to the large share of this segment.

An in-depth analysis of the geographical scenario of the global CAR T-cell therapy market provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the CAR T-cell Therapy market. In 2023, the U.S. is expected to account for the largest share of the CAR T-cell Therapy market in North America. The large share of this regional market is attributed to the presence of major CAR T-cell Therapy companies such as bluebird bio, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), and Caribou Biosciences, Inc. (U.S.), increasing cancer prevalence, a rise in awareness regarding CAR T-cell therapy, and increasing R&D activities and clinical trials in the region.

Scope of the Report:

CAR T-cell Therapy Market Assessment-by Drug Type

• Abecma (idecabtagene vicleucel)
• Breyanzi (lisocabtagene maraleucel)
• Kymriah (tisagenlecleucel)
• Tecartus (brexucabtagene autoleucel)
• Yescarta (axicabtagene ciloleucel)
• Carvykti (ciltacabtagene autoleucel)
• Other Brands

CAR T-cell Therapy Market Assessment-by Target Antigen

• CD
• BCMA
• HER2
• Other Target Antigens

Note: Other target antigens include EGFR, GD2, MUC16, Lewis Y, and ROR1

CAR T-cell Therapy Market Assessment-by Indication

• Lymphoma
• Acute Lymphoblastic Leukemia
• Multiple Myeloma
• Acute Myeloid Leukemia
• Other Indications

Note: Other indications include pancreatic cancer, breast cancer, ovarian cancer, scleroderma, HIV/AIDs, and autoimmune diseases.

CAR T-cell Therapy Market Assessment-by Geography

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• U.K
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• Rest of Asia-Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Overview

• 1.1. Market Definition & Scope
• 1.2. Market Ecosystem
• 1.3. Currency and Limitation
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process Data Collection & Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
• 2.3. Market Sizing and Forecast
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
• 2.4. Assumptions for the Study
• 2.5. Limitations for the Study

3. Executive Summary

4. Factors Affecting Market Growth

• 4.1. Overview
• 4.2. Drivers
  • 4.2.1. Increasing Cancer Prevalence
  • 4.2.2. Rise in Awareness Regarding CAR T-cell Therapy
  • 4.2.3. Increasing R&D Activities and Clinical Trials
• 4.3. Restraints
  • 4.3.1. Complex Manufacturing Process
  • 4.3.2. Adverse Effects of the Therapy
• 4.4. Opportunities
  • 4.4.1. Scope in Emerging Economies
  • 4.4.2. Innovation in Cell Therapies and Manufacturing Processes
• 4.5. Challenges
  • 4.5.1. High Cost of Therapy
  • 4.5.2. Lack of Skilled Professionals
• 4.6. Regulatory Analysis
• 4.7. Pricing Analysis
• 4.8. Pipeline Product Analysis
• 4.9. Patient Journey
• 4.10. Reimbursement Policies
• 4.11. Porters Five Forces Analysis

5. Global CAR T-cell Therapy Market & Trend Analysis-by Brand

• 5.1. Overview
• 5.2. Abecma (idecabtagene vicleucel)
• 5.3. Breyanzi (lisocabtagene maraleucel)
• 5.4. Kymriah (tisagenlecleucel)
• 5.5. Tecartus (brexucabtagene autoleucel)
• 5.6. Yescarta (axicabtagene ciloleucel)
• 5.7. Carvykti (ciltacabtagene autoleucel)
• 5.8. Other Brands

6. Global CAR T-cell Therapy Market & Trend Analysis-by Target Antigen

• 6.1. Overview
• 6.2. CD
• 6.3. BCMA
• 6.4. HER2
• 6.5. Other Target Antigens

7. Global CAR T-cell Therapy Market & Trend Analysis-by Indication

• 7.1. Overview
• 7.2. Lymphoma
• 7.3. Acute Lymphoblastic Leukemia
• 7.4. Multiple Myeloma
• 7.5. Acute Myeloid Leukemia
• 7.6. Other Indications

8. CAR T-cell Therapy Market & Trend Analysis-by Geography

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. U.S.
  • 8.2.2. Canada
• 8.3. Europe
  • 8.3.1. Germany
  • 8.3.2. France
  • 8.3.3. U.K.
  • 8.3.4. Italy
  • 8.3.5. Spain
  • 8.3.6. Rest of Europe
• 8.4. Asia-Pacific
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Rest of Asia-Pacific
• 8.5. Latin America
• 8.6. Middle East & Africa

9. Competitive Analysis

• 9.1. Overview
• 9.2. Key Growth Strategies
• 9.3. Vendor Market Positioning
• 9.4. Competitive Dashboard
  • 9.4.1. Industry Leaders
  • 9.4.2. Market Differentiators
  • 9.4.3. Vanguards
  • 9.4.4. Emerging Companies
• 9.5. Market Share Analysis/Market Ranking (2022)

10. Company Profiles (Business Overview, Financial Snapshot, Product Portfolio, Strategic Developments, and SWOT Analysis)

• 10.1. Novartis AG
• 10.2. bluebird bio, Inc.
• 10.3. Bristol-Myers Squibb Company
• 10.4. Caribou Biosciences, Inc.
• 10.5. Cartesian Therapeutics, Inc.
• 10.6. Pfizer Inc.
• 10.7. Cellectis S.A.
• 10.8. Celyad Oncology SA
• 10.9. Gilead Sciences, Inc.
• 10.10. Intellia Therapeutics, Inc.
• 10.11. Merck & Co., Inc.
• 10.12 Amgen Inc.
• 10.13. Inovio Pharmaceuticals, Inc.
• 10.14. OncoTherapy Science, Inc.
• 10.15. Other Companies

11. Appendix

• 11.1. Questionnaire
• 11.2. Available Customization